KPV

Research

KPV (Lysine-Proline-Valine)

Aliases
alpha-MSH fragment
Administration
Subcutaneous injection (research), Oral (research), Topical (research)

Research and regulatory

Development stage

Preclinical (extensive rodent models of colitis and skin inflammation); no known human clinical trials.

Legal and regulatory

Unscheduled research compound; not FDA approved. In July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8-6 to recommend KPV for the 503A Bulks List, which would make it eligible for pharmacy compounding — this is a recommendation only, not yet legal to compound, pending formal FDA rulemaking.

Side effects

Limited data on human side effects